Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Cheryl Ho, MD, FRCP(C)

Clinical Associate Professor
University of British Columbia
Medical Oncologist
British Columbia Cancer
Vancouver, BC

Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.

Randeep Sangha, MD, FRCPC

Associate Professor, University of Alberta
Medical Oncologist, Cross Cancer Institute
Director, Clinical Trials Unit, Cross Cancer Institute
Provincial Lead, Alberta Lung Cancer Program
Edmonton, AB

Randeep Sangha, MD, is an Associate Professor at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada.

Dr. Sangha obtained his medical degree from the University of Alberta Faculty of Medicine, where he also completed his his residency in Internal Medicine and Medical Oncology. He then pursued a post-training research fellowship at the University of California, Davis Comprehensive Cancer Center, focusing on thoracic malignancies.

Dr. Sangha is the Director of the Clinical Trials Unit at the Cross Cancer Institute. He also has been the Provincial Lead for the Alberta Lung Cancer Program. His clinical and research interests include treatment of thoracic and hematologic malignancies, as well as developmental and molecular therapeutics.

Devin Schellenberg, MD, FRCS(C)

Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto.  He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.

Dan Palhares, MD, MSc

Assistant Professor, McMaster University
Radiation Oncologist, Juravinski Cancer Center, Hamilton Health Sciences
Hamilton, ON

Dr. Dan Palhares is a Radiation Oncologist at the Juravinski Cancer Centre and Assistant Professor at McMaster University. His clinical and research interests focus on lung and brain cancers, with particular expertise in stereotactic body radiotherapy (SBRT), imaging biomarkers, and clinical trials. He has authored 42 peer-reviewed publications in leading journals, including The Lancet Oncology, Nature Precision Oncology, and the Red and Green Journals, and has received eight research awards.

Riyaz Shah, MD

Medical Oncologist, Kent Oncology Centre, Maidstone Hospital
Member, BTOG steering committee
England, UK

Dr. Shah is a thoracic medical oncologist practising in Kent and London. He has been intimately involved in multiple clinical trials over his career and works with NHS England to optimize the delivery of lung cancer genomics. He is an early adopter and champion for liquid and tissue genomics in lung systemic therapy. As a steering committee member of BTOG, he is extensively involved in organizing and delivering educational events at a national level. As an active member of IASLC, he works to improve education internationally. He is a clinical advisor to the UK patient support/advocacy groups “EGFR Lung Cancer UK” and “UKALK+”.

Prof. Ben J. Slotman, MD, PhD, FASTRO, FARS, hFACR

Professor of Radiation Oncology, Amsterdam University Medical Center
Board Member, American Society for Radiation Oncology, United States
Board Member, European Society for Radiotherapy and Oncology, Europe
Amsterdam, Netherlands

Prof. Ben Slotman (born 1959) has been a professor of radiation oncology since 1998 and served as chair of the Department of Radiation Oncology at the VU University Medical Center and later Amsterdam University Medical Center from 1996 to 2024, where he also helped integrate the VUmc and AMC departments into one of Europe’s largest radiation oncology centres. His expertise includes high-precision and stereotactic radiotherapy, small cell lung cancer treatment, and early clinical implementation of new technologies, and he has authored over 500 scientific publications and led numerous international clinical trials and conferences that influenced global treatment standards. He earned his medical degree cum laude in 1985 and his PhD cum laude in 1990 from Vrije Universiteit Amsterdam, became a registered radiation oncologist in 1994, and was appointed professor in 1998; he also held leadership roles including division chair, vice-chair of Imaging at Amsterdam UMC, and professor emeritus from 2026. Internationally, he has served as president or board member of major organizations including ASTRO, ESTRO, the American Radium Society, and the Radiosurgery Society, and founded the International Radiation Oncology Societies Network in 2022. His contributions have been widely recognized with honours such as fellowships from the American College of Radiology, ASTRO, and the American Radium Society, the Jack Fabrikant Award, and knighthood in the Order of the Dutch Lion, along with honorary membership in the Dutch Society for Radiotherapy and Oncology.